← Liquidia overview

Liquidia vs Bristol-Myers Squibb: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Liquidia Technologies Inc (LQDA)

Q3 2026
▲2▼2

Yutrepia Launch Booms, Then Patent Ruling Threatens Key Market

  • Yutrepia launch exceeds expectations Yutrepia's launch delivered strong growth: annualized revenue hit about $520 million, with $300 million in first-half sales, over 5,000 patients started, and four straight profitable quarters. Analysts raised estimates as the stock more than doubled.

    This is the main positive force behind the stock's rise during the period.

  • Patent ruling threatens PH-ILD market A Delaware court ruled that Yutrepia infringes a United Therapeutics patent covering PH-ILD use, threatening a key market and future sales. This legal setback reversed earlier momentum and weighed heavily on the stock.

    This is the major negative event that changed the stock's trajectory.

  • Analyst downgrades and price target cuts Wells Fargo, BTIG, and Raymond James downgraded the stock and sharply cut price targets following the patent ruling, reflecting reduced confidence in future sales and earnings.

    These downgrades amplified the negative impact of the patent ruling on the stock price.

  • FDA Fast Track for Raynaud's The FDA granted Fast Track status for Yutrepia in scleroderma-related Raynaud's phenomenon, a smaller, early-stage opportunity that partly offsets the negative patent news.

    This is a new positive development that provides some counterbalance to the negative drivers.

September 2026
▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

  • Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.

    It shows the core business is growing fast, which is the main force pushing LQDA up.

  • Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.

    This is the biggest new negative force, directly threatening a major part of Yutrepia's market.

  • Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.

    It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.

  • Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.

    It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

Latest
▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

  • Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.

    It shows the core business is growing fast, which is the main force pushing LQDA up.

  • Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.

    This is the biggest new negative force, directly threatening a major part of Yutrepia's market.

  • Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.

    It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.

  • Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.

    It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

July 2026
▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

  • Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.

    This is the core fundamental driver of LQDA's price surge.

  • Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.

    This is a new legal development that directly affects the key risk overhang on the stock.

  • Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.

    These metrics demonstrate the strength of the launch and its potential for continued growth.

  • Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.

    This shows third-party validation and improving earnings expectations, which drive stock price.

▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

  • Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.

    This is the core fundamental driver of LQDA's price surge.

  • Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.

    This is a new legal development that directly affects the key risk overhang on the stock.

  • Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.

    These metrics demonstrate the strength of the launch and its potential for continued growth.

  • Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.

    This shows third-party validation and improving earnings expectations, which drive stock price.

Bristol-Myers Squibb Company (BMY)

Q3 2026
▲3▼1

Bristol-Myers Q3: Pipeline Wins, Financial Beat, But Competitive and Legal Risks Loom

  • Strong Q2 results and raised guidance Bristol reported Q2 revenue of about $13 billion and a 40% jump in earnings per share, prompting management to raise full-year revenue guidance to $49–50 billion. Analysts also increased their 2026 EPS estimates to $6.91.

    This shows the company's core financial performance and improved outlook, a key positive driver for the stock.

  • Pipeline and regulatory progress The FDA accepted mezigdomide for review, approved ZENBEXUS for multiple myeloma, and expanded Camzyos to treat pediatric patients. These advances strengthen Bristol's product lineup and help offset future patent losses.

    New drug approvals and expanded uses are direct growth catalysts that can drive future sales and investor confidence.

  • AI and infrastructure investments Bristol partnered with NVIDIA, Schrödinger, and Chai Discovery on AI-driven drug discovery, and opened a new San Diego hub and Houston plant. These investments aim to speed up research and expand manufacturing capacity.

    Long-term growth initiatives that could improve efficiency and innovation, supporting the stock's future potential.

  • Competitive and legal pressures Cytokinetics' Myqorzo threatens Camzyos, J&J's psoriasis pill challenges Sotyktu in China, and AstraZeneca merger talks collapsed. A $6.7B Celgene lawsuit revived, and CAR-T trials paused after Novartis deaths.

    These setbacks create uncertainty and potential revenue loss, weighing on the stock price.

September 2026
▲2▼2

BMY pipeline advances, but competition and safety concerns weigh

  • Pipeline and label expansion Zenbexus won FDA accelerated approval for relapsed multiple myeloma, Camzyos expanded to pediatric patients, and Arlo-cel met its Phase 2 endpoint, strengthening BMY's growth prospects.

    This is a key positive development that could drive future revenue and investor optimism.

  • Analyst EPS estimate raise Growth products now make up 56% of revenue, leading analysts to raise 2026 EPS estimates to $6.91 from $6.34, reflecting confidence in BMY's earnings power.

    This shows improved financial outlook and analyst confidence, which can positively impact the stock.

  • Competitive threat to Sotyktu J&J's oral psoriasis pill won Chinese approval, threatening Sotyktu in a market of over 8 million patients, potentially limiting BMY's growth in a key segment.

    This competitive pressure could hurt BMY's market share and revenue, a negative for the stock.

  • CAR-T trial pause Bristol paused CAR-T trials after Novartis deaths, raising regulatory and safety concerns that could delay development and pressure the stock.

    This introduces uncertainty and potential setbacks in a promising area, negatively impacting investor sentiment.

Latest
▲4

Bristol's Growth Portfolio Accelerates with New Drug Approvals and Strong Pipeline Data

  • Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

    Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

  • Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

    A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

  • Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

    Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

  • Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

    Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

▲3▼2

Bristol's Cancer Pipeline Advances, but Competition and Safety Fears Linger

  • Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

    This is a new drug approval that directly adds a future revenue driver for BMY.

  • J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

    New competitive threat in a key market that could slow BMY's psoriasis drug sales.

  • Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

    New clinical data that supports the durability and safety of a key growth drug.

  • CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

    New safety event that directly affects BMY's CAR-T development and investor risk perception.

  • Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

    New positive clinical trial result that advances a potential new therapy for BMY.

August 2026
▲2▼2

BMY beats on earnings, raises guidance, but merger talks collapse

  • Strong Q2 earnings and raised guidance Bristol-Myers Squibb reported Q2 revenue of about $13 billion, beating estimates, with earnings per share jumping 40% to $2.04. Management raised full-year guidance twice, ending at $49–50 billion, driven by Eliquis (+19%) and newer drugs like Camzyos and Reblozyl.

    This is the main positive force behind BMY's stock in August, showing better-than-expected financial performance and improved outlook.

  • FDA approves ZENBEXUS and AI partnerships expand The FDA approved ZENBEXUS for multiple myeloma, adding a new treatment to Bristol's portfolio. The company also expanded AI partnerships with Nvidia, Schrödinger, and Chai Discovery, and announced a $2.3 billion Houston plant, supporting long-term growth.

    These new developments strengthen BMY's pipeline and manufacturing, offering future revenue potential.

  • AstraZeneca merger talks collapse Reported merger talks with AstraZeneca fell apart, removing a potential takeover premium that had lifted BMY's stock. Without a merger, Bristol faces its patent cliff alone, increasing pressure to replace lost revenue from older drugs.

    This is a major negative event that removed a catalyst and leaves BMY more vulnerable to patent expirations.

  • Revived $6.7 billion Celgene lawsuit A $6.7 billion lawsuit related to the Celgene acquisition has been revived, adding legal and financial uncertainty. This could raise BMY's risk premium and pressure the stock as investors weigh potential liabilities.

    This new legal issue introduces uncertainty and potential financial burden, negatively impacting investor sentiment.

▲3▼1

Bristol Raises Outlook, Expands AI and Manufacturing Despite Legal and Competitive Risks

  • Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

    This is the most significant new positive catalyst, directly raising revenue and profit outlook.

  • Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

    This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

  • Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

    This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

  • Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

    This new legal development introduces a significant potential liability, a negative factor for the stock.

▲3▼1

Bristol's Q2 Beat and New Drug Approval Offset Failed Merger

  • Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

    This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

  • AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

    The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

  • FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

    This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

  • Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

    These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

▲2

Bristol Q2 Beat and AstraZeneca Merger Talk Lift BMY

  • Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

    This is the core fundamental news of the period and directly supports a higher valuation for BMY.

  • Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

    This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

  • Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

    It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

July 2026
▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

Q2 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

June 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

© 2026 MarketIVWhy